Axsome Therapeutics Inc

AXSMNASDAQ · USD
132.37USD+2.57 (+1.98%)
317

Axsome Therapeutics Inc (AXSM) Covered Calls

Axsome Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 87.70%, high versus the past year. AXSM's highest covered call setup is the $280.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 100.56% out of the money with 45 days to expiration, a 100.59% return until expiration, and a 815.93% theoretical annualized return. Across the setups shown, annualized returns run from 264.87% to 815.93% at strikes between $160.00 and $280.00, with 17 to 73 days to expiration, as of Nov 3, 2026.

Read more

Running AXSM covered calls helps you generate income from Axsome Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AXSM covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AXSM stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AXSM covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AXSM covered call is worth writing.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.

2026-12-1845280.00100.560.050.5014044.00100.59815.93-0.04+0.02210.45
2026-11-2017170.0021.770.150.903054.0021.88469.67-0.11+0.07480.75
2026-12-1845210.0050.420.101.207049.0050.49409.54-0.07+0.052111.10
2026-11-2017165.0018.190.051.852544.0018.22391.24-0.04+0.111,0581.80
2027-01-1573240.0071.910.102.0510049.0071.98359.90-0.07+0.063511.95
2026-12-1845195.0039.670.302.405569.0039.89323.55-0.21+0.10452.10
2026-11-2017160.0014.600.252.552064.0014.78317.42-0.18+0.162772.30
2026-12-1845190.0036.090.502.455089.0036.45295.66-0.36+0.11251.95
2027-01-1573220.0057.580.052.458044.0057.62288.09-0.04+0.085562.40
2026-12-1845185.0032.510.203.304559.0032.66264.87-0.14+0.1373.10

As of Nov 3, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank87.70% High
  • Market cap (M$)6,827
  • 52 weeks high-50.11%
  • 52 weeks low5.53%
  • Analyst recommendationStrong Buy
    1.13
  • Target price$265.86
    109.91% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-02
  • P/E—
  • Future P/E36.71
  • EPS (ttm)-3.06
  • EPS growth next 5 years—

As of Nov 5, 2026